...
首页> 外文期刊>Nephrology Dialysis Transplantation >Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminurian and other cardiovascular risk factors: a systematic review of randomized controlled trials
【24h】

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminurian and other cardiovascular risk factors: a systematic review of randomized controlled trials

机译:血管紧张素转换酶抑制剂,血管紧张素受体阻滞剂和联合治疗对微白蛋白尿和大白蛋白尿及其他心血管疾病危险因素的患者:随机对照试验的系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Background. A recent clinical trial showed harmful renal effects with the combined use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) in people with diabetes or vascular disease. We examined the benefits and risks of these agents in people with albuminuria and one or more cardiovascular risk factors.
机译:背景。最近的一项临床试验表明,在糖尿病或血管疾病患者中,合并使用血管紧张素转换酶抑制剂(ACEI)和血管紧张素II受体阻滞剂(ARB)会对肾脏产生有害影响。我们检查了这些药物对白蛋白尿和一种或多种心血管危险因素的益处和风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号